http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Vishwakarma, Santosh L.,Rajani, M.,Goyal, Ramesh K. Kyung Hee Oriental Medicine Research Center 2003 Oriental pharmacy and experimental medicine Vol.3 No.4
Aqueous extract of Enicostemma littorale is reported to have antidiabetic activity. In the present investigation, we studied the effect of aqueous extract of E. littorale and its different fractions i.e., toluene, chloroform, ethyl acetate, n-butanol fractions and remaining residual fraction in streptozotocin (STZ)-induced neonatal type 2 diabetic rats. Fasting glucose and insulin levels in NIDDM were significantly (P<0.05) higher than control rats and they were significantly decreased by treatment with aqueous extract of E. littorale and its n-butanol and ethyl acetate fractions. Results of oral glucose tolerance test (OGTT) showed that aqueous extract and its n-butanol and ethyl acetate fractions significantly (P<0.05) decrease both $AUC_{glucose}$ and $AUC_{insulin}$ values in NIDDM treated groups. Insulin sensitivity $(K_{ITT})$ index of NIDDM control was significantly lower as compared to normal control and this was significantly (P<0.05) increased after treatment with aqueous extract, its n-butanol and ethyl acetate fractions. Treatment with aqueous extract of E. littorale and its n-butanol and ethyl acetate fractions lowered the elevated cholesterol and triglyceride levels observed in NIDDM rats. Treatment with aqueous extract of E. littorale and its n-butanol fraction showed significant decrease in creatinine, urea, SGPT and SGOT levels as compared to NIDDM control rats. However ethyl acetate fraction showed significant changes only in creatinine and SGOT levels, and not in the levels of urea, and SGPT as compared to NIDDM control rats. Treatment with toluene, chloroform and residual fractions of E. littorale did not produce any effect on glucose, insulin, triglyceride, cholesterol, creatinine, urea, SGPT or SGOT levels as compared to NIDDM control rats. Our data suggest that n-butanol and ethyl acetate fractions contain the active compounds which may be responsible for the above activity and associated complications in NIDDM diabetes mellitus.
Nagaraj M. Kulkarni,Milind M. Muley,Mallikarjun S. Jaji,G. Vijaykanth,J. Raghul,Neetin Kumar D. Reddy,Santosh L. Vishwakarma,Navin B. Rajesh,Jeyamurugan Mookkan,Uma Maheswari Krishnan,Shridhar Narayan 대한약학회 2015 Archives of Pharmacal Research Vol.38 No.6
Atorvastatin is a 3-hydroxy-3-methylglutarylcoenzyme-A reductase inhibitor used in the treatment ofatherosclerosis and dyslipidemia. Studies have evaluatedthe utility of statins in the treatment of skin inflammationbut with varied results. In the present study, we investigatedthe effect of atorvastatin on TNF-a release andkeratinocyte proliferation in vitro and in acute and chronic12-O-tetradecanoylphorbol-13-acetate (TPA) induced skininflammation in vivo. Atorvastatin significantly inhibitedlipopolysacharide induced TNF-a release in THP-1 cellsand keratinocyte proliferation in HaCaT cells. In an acutestudy, topical atorvastatin showed dose dependent reductionin TPA induced skin inflammation with highest efficacyobserved at 500 lg/ear dose. In chronic study, topicalatorvastatin significantly reduced TPA induced ear thickness,ear weight, cutaneous cytokines, MPO activity andimproved histopathological features comparable to that ofdexamethasone. Atorvastatin also inhibited TPA stimulatedNF-jB activation in mouse ear. In conclusion, our resultssuggest that atorvastatin ameliorates TPA induced skininflammation in mice at least in part, due to inhibition ofcytokine release and NF-jB activation and may be beneficialfor the treatment skin inflammation like psoriasis.